Top

Published in:

01-12-2020 | Cholangiocarcinoma | ASO Author Reflections

ASO Author Reflections: Adjuvant Chemoradiation for Patients with Resected Biliary Tract Cancers

Authors: Edward Christopher Dee, BS, Morgan E. Freret, MD, PhD, Jennifer Y. Wo, MD

Published in: Annals of Surgical Oncology | Issue 13/2020

Excerpt

Biliary tract cancers (BTCs), comprising gallbladder carcinoma (GBC), extrahepatic cholangiocarcinoma (eCCA), and intrahepatic cholangiocarcinoma (iCCA), confer significant morbidity and mortality.1 Only approximately 20% of patients have resectable disease at diagnosis.1 Postoperative survival is approximately 18 to 30 months, with positive resection margins (R1 vs R0) and positive lymph node status conveying a worse prognosis.2 Until the recently published prospective trials, treatment decisions in the adjuvant setting had been guided by retrospective nonrandomized series and consensus guidelines.1 Dee et al.3 report an analysis of 80 patients who had resected BTCs treated with adjuvant chemoradiation therapy (CRT) from 2007 to 2017 at the Massachusetts General Hospital (MGH). …

Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015–27. https://doi.org/10.1200/jco.18.02178.CrossRefPubMed

DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–62. https://doi.org/10.1097/01.sla.0000251366.62632.d3.CrossRefPubMedPubMedCentral

Dee EC, Freret ME, Horick N, et al. Patterns of failure and need for biliary intervention in resected biliary tract cancers after chemoradiation. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08967-9.

Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202. https://doi.org/10.1002/bjs.10776.CrossRefPubMed

Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (Prodige 12-accord 18-Unicancer GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–667. https://doi.org/10.1200/jco.18.00050.CrossRefPubMed

Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–673. https://doi.org/10.1016/s1470-2045(18)30915-x.CrossRef

Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33:2617–22. https://doi.org/10.1200/jco.2014.60.2219.CrossRefPubMed

Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–40. https://doi.org/10.1200/jco.2011.40.5381.CrossRefPubMed

Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D, Ferté C. Matching genomic molecular aberrations with molecular targeted agents: are biliary tract cancers an ideal playground? Eur J Cancer. 2017;81:161–173. https://doi.org/10.1016/j.ejca.2017.05.006.CrossRef

10.

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7:943–62. https://doi.org/10.1158/2159-8290.cd-17-0245.CrossRefPubMedPubMedCentral

Title: ASO Author Reflections: Adjuvant Chemoradiation for Patients with Resected Biliary Tract Cancers
Authors: Edward Christopher Dee, BS
Morgan E. Freret, MD, PhD
Jennifer Y. Wo, MD
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Published in: Annals of Surgical Oncology / Issue 13/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-08970-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ASO Author Reflections: Adjuvant Chemoradiation for Patients with Resected Biliary Tract Cancers

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2020

Laparoscopic Central Bisectionectomy Including Resection of the Segment 7 Using the Extrahepatic Glissonean Approach and Hepatic Vein Guidance

Prognostic Impact of Budding Grade in Patients With Residual Liver Recurrence of Colorectal Cancer After Initial Hepatectomy

The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC

Simultaneous Ipsilateral Vascularized Lymph Node Transplantation and Contralateral Lymphovenous Anastomosis in Bilateral Extremity Lymphedema with Different Severities

Pelvic Anastomosis Without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Predicting Survival in Colorectal Liver Metastasis: Time for New Approaches